Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Hip Osteoarthritis Pain Drug Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Hip Osteoarthritis Pain Drug Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Oral
1.3.3 Injection
1.3.4 External
1.4 Market Segment by Application
1.4.1 Global Hip Osteoarthritis Pain Drug Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Medical Care
1.4.3 Personal Care
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Hip Osteoarthritis Pain Drug Revenue (2015-2026)
2.1.1 Global Hip Osteoarthritis Pain Drug Revenue (2015-2026)
2.1.2 Global Hip Osteoarthritis Pain Drug Sales (2015-2026)
2.2 Hip Osteoarthritis Pain Drug Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Hip Osteoarthritis Pain Drug Sales by Regions (2015-2020)
2.2.2 Global Hip Osteoarthritis Pain Drug Revenue by Regions (2015-2020)
2.3 Global Top Hip Osteoarthritis Pain Drug Regions (Countries) Ranking by Market Size
2.4 Hip Osteoarthritis Pain Drug Industry Trends
2.4.1 Hip Osteoarthritis Pain Drug Market Top Trends
2.4.2 Market Drivers
2.4.3 Hip Osteoarthritis Pain Drug Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Hip Osteoarthritis Pain Drug Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Hip Osteoarthritis Pain Drug Manufacturers by Sales (2015-2020)
3.1.1 Global Hip Osteoarthritis Pain Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Hip Osteoarthritis Pain Drug Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Hip Osteoarthritis Pain Drug Sales in 2019
3.2 Global Top Manufacturers Hip Osteoarthritis Pain Drug by Revenue
3.2.1 Global Hip Osteoarthritis Pain Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Hip Osteoarthritis Pain Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hip Osteoarthritis Pain Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hip Osteoarthritis Pain Drug as of 2019)
3.4 Global Hip Osteoarthritis Pain Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Hip Osteoarthritis Pain Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Hip Osteoarthritis Pain Drug Market
3.7 Key Manufacturers Hip Osteoarthritis Pain Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Hip Osteoarthritis Pain Drug Historic Market Review by Type (2015-2020)
4.1.2 Global Hip Osteoarthritis Pain Drug Sales Market Share by Type (2015-2020)
4.1.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Type (2015-2020)
4.1.4 Hip Osteoarthritis Pain Drug Price by Type (2015-2020)
4.1 Global Hip Osteoarthritis Pain Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Hip Osteoarthritis Pain Drug Sales Forecast by Type (2021-2026)
4.2.3 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Type (2021-2026)
4.2.4 Hip Osteoarthritis Pain Drug Price Forecast by Type (2021-2026)
5 Global Hip Osteoarthritis Pain Drug Market Size by Application
5.1 Global Hip Osteoarthritis Pain Drug Historic Market Review by Application (2015-2020)
5.1.2 Global Hip Osteoarthritis Pain Drug Sales Market Share by Application (2015-2020)
5.1.3 Global Hip Osteoarthritis Pain Drug Revenue Market Share by Application (2015-2020)
5.1.4 Hip Osteoarthritis Pain Drug Price by Application (2015-2020)
5.2 Global Hip Osteoarthritis Pain Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Hip Osteoarthritis Pain Drug Sales Forecast by Application (2021-2026)
5.2.3 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Application (2021-2026)
5.2.4 Hip Osteoarthritis Pain Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hip Osteoarthritis Pain Drug Breakdown Data by Company
6.2 North America Hip Osteoarthritis Pain Drug Breakdown Data by Type
6.3 North America Hip Osteoarthritis Pain Drug Breakdown Data by Application
6.4 North America Hip Osteoarthritis Pain Drug Breakdown Data by Countries
6.4.1 North America Hip Osteoarthritis Pain Drug Sales by Countries
6.4.2 North America Hip Osteoarthritis Pain Drug Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Company
7.2 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Type
7.3 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Application
7.4 Europe Hip Osteoarthritis Pain Drug Breakdown Data by Countries
7.4.1 Europe Hip Osteoarthritis Pain Drug Sales by Countries
7.4.2 Europe Hip Osteoarthritis Pain Drug Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Company
8.2 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Type
8.3 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Application
8.4 Asia Pacific Hip Osteoarthritis Pain Drug Breakdown Data by Regions
8.4.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales by Regions
8.4.2 Asia Pacific Hip Osteoarthritis Pain Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Hip Osteoarthritis Pain Drug Breakdown Data by Company
9.2 Latin America Hip Osteoarthritis Pain Drug Breakdown Data by Type
9.3 Latin America Hip Osteoarthritis Pain Drug Breakdown Data by Application
9.4 Latin America Hip Osteoarthritis Pain Drug Breakdown Data by Countries
9.4.1 Latin America Hip Osteoarthritis Pain Drug Sales by Countries
9.4.2 Latin America Hip Osteoarthritis Pain Drug Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Type
10.2 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Application
10.3 Middle East and Africa Hip Osteoarthritis Pain Drug Breakdown Data by Countries
10.3.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales by Countries
10.3.2 Middle East and Africa Hip Osteoarthritis Pain Drug Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Pfizer Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Pfizer Hip Osteoarthritis Pain Drug Products and Services
11.1.5 Pfizer SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 Johnson and Johnson
11.2.1 Johnson and Johnson Corporation Information
11.2.2 Johnson and Johnson Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Johnson and Johnson Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Johnson and Johnson Hip Osteoarthritis Pain Drug Products and Services
11.2.5 Johnson and Johnson SWOT Analysis
11.2.6 Johnson and Johnson Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Business Overview and Total Revenue (2019 VS 2018)
11.3.3 GlaxoSmithKline Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline Hip Osteoarthritis Pain Drug Products and Services
11.3.5 GlaxoSmithKline SWOT Analysis
11.3.6 GlaxoSmithKline Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Bayer Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Bayer Hip Osteoarthritis Pain Drug Products and Services
11.4.5 Bayer SWOT Analysis
11.4.6 Bayer Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Corporation Information
11.5.2 Eli Lilly Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Eli Lilly Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Eli Lilly Hip Osteoarthritis Pain Drug Products and Services
11.5.5 Eli Lilly SWOT Analysis
11.5.6 Eli Lilly Recent Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Novartis Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Novartis Hip Osteoarthritis Pain Drug Products and Services
11.6.5 Novartis SWOT Analysis
11.6.6 Novartis Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Sanofi Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Sanofi Hip Osteoarthritis Pain Drug Products and Services
11.7.5 Sanofi SWOT Analysis
11.7.6 Sanofi Recent Developments
11.8 Horizon Pharma
11.8.1 Horizon Pharma Corporation Information
11.8.2 Horizon Pharma Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Horizon Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Horizon Pharma Hip Osteoarthritis Pain Drug Products and Services
11.8.5 Horizon Pharma SWOT Analysis
11.8.6 Horizon Pharma Recent Developments
11.9 Abbott
11.9.1 Abbott Corporation Information
11.9.2 Abbott Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Abbott Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Abbott Hip Osteoarthritis Pain Drug Products and Services
11.9.5 Abbott SWOT Analysis
11.9.6 Abbott Recent Developments
11.10 Mylan
11.10.1 Mylan Corporation Information
11.10.2 Mylan Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Mylan Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Mylan Hip Osteoarthritis Pain Drug Products and Services
11.10.5 Mylan SWOT Analysis
11.10.6 Mylan Recent Developments
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Corporation Information
11.11.2 Daiichi Sankyo Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Daiichi Sankyo Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Daiichi Sankyo Hip Osteoarthritis Pain Drug Products and Services
11.11.5 Daiichi Sankyo SWOT Analysis
11.11.6 Daiichi Sankyo Recent Developments
11.12 TEVA
11.12.1 TEVA Corporation Information
11.12.2 TEVA Business Overview and Total Revenue (2019 VS 2018)
11.12.3 TEVA Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 TEVA Hip Osteoarthritis Pain Drug Products and Services
11.12.5 TEVA SWOT Analysis
11.12.6 TEVA Recent Developments
11.13 Almatica Pharma
11.13.1 Almatica Pharma Corporation Information
11.13.2 Almatica Pharma Business Overview and Total Revenue (2019 VS 2018)
11.13.3 Almatica Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 Almatica Pharma Hip Osteoarthritis Pain Drug Products and Services
11.13.5 Almatica Pharma SWOT Analysis
11.13.6 Almatica Pharma Recent Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Corporation Information
11.14.2 Astellas Pharma Business Overview and Total Revenue (2019 VS 2018)
11.14.3 Astellas Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.14.4 Astellas Pharma Hip Osteoarthritis Pain Drug Products and Services
11.14.5 Astellas Pharma SWOT Analysis
11.14.6 Astellas Pharma Recent Developments
11.15 Tide Pharmaceutical
11.15.1 Tide Pharmaceutical Corporation Information
11.15.2 Tide Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.15.3 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.15.4 Tide Pharmaceutical Hip Osteoarthritis Pain Drug Products and Services
11.15.5 Tide Pharmaceutical SWOT Analysis
11.15.6 Tide Pharmaceutical Recent Developments
11.16 Iroko Pharmaceuticals
11.16.1 Iroko Pharmaceuticals Corporation Information
11.16.2 Iroko Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.16.3 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.16.4 Iroko Pharmaceuticals Hip Osteoarthritis Pain Drug Products and Services
11.16.5 Iroko Pharmaceuticals SWOT Analysis
11.16.6 Iroko Pharmaceuticals Recent Developments
11.17 Hengrui Pharmaceutical
11.17.1 Hengrui Pharmaceutical Corporation Information
11.17.2 Hengrui Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.17.3 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.17.4 Hengrui Pharmaceutical Hip Osteoarthritis Pain Drug Products and Services
11.17.5 Hengrui Pharmaceutical SWOT Analysis
11.17.6 Hengrui Pharmaceutical Recent Developments
11.18 Abiogen Pharma
11.18.1 Abiogen Pharma Corporation Information
11.18.2 Abiogen Pharma Business Overview and Total Revenue (2019 VS 2018)
11.18.3 Abiogen Pharma Hip Osteoarthritis Pain Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.18.4 Abiogen Pharma Hip Osteoarthritis Pain Drug Products and Services
11.18.5 Abiogen Pharma SWOT Analysis
11.18.6 Abiogen Pharma Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Hip Osteoarthritis Pain Drug Sales Channels
12.2.2 Hip Osteoarthritis Pain Drug Distributors
12.3 Hip Osteoarthritis Pain Drug Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.1.1 Global Hip Osteoarthritis Pain Drug Sales Forecast by Regions (2021-2026)
13.1.2 Global Hip Osteoarthritis Pain Drug Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.2.2 North America Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.2.3 North America Hip Osteoarthritis Pain Drug Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.3.2 Europe Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.3.3 Europe Hip Osteoarthritis Pain Drug Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.4.2 Asia Pacific Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Hip Osteoarthritis Pain Drug Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.5.2 Latin America Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.5.3 Latin America Hip Osteoarthritis Pain Drug Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Hip Osteoarthritis Pain Drug Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Hip Osteoarthritis Pain Drug Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Hip Osteoarthritis Pain Drug Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Pfizer、Johnson and Johnson、GlaxoSmithKline、Bayer、Eli Lilly、Novartis、Sanofi、Horizon Pharma、Abbott、Mylan、Daiichi Sankyo、TEVA、Almatica Pharma、Astellas Pharma、Tide Pharmaceutical、Iroko Pharmaceuticals、Hengrui Pharmaceutical、Abiogen Pharma
【免責事項】
https://www.globalresearch.jp/disclaimer